Freeline Therapeutics Holdings Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Freeline Therapeutics Holdings hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$11.45
Erwartete Dividendenrendite in 3 Jahren	15.4%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Calculating The Intrinsic Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)

Jul 13

Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

Apr 11

Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

Dec 20

We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate

Aug 30

Freeline gains as NEJM publishes long-term data for hemophilia therapy

Jul 21

Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Invest In Growth?

May 05

Will Freeline Therapeutics Holdings (NASDAQ:FRLN) Spend Its Cash Wisely?

Jan 13

Companies Like Freeline Therapeutics Holdings (NASDAQ:FRLN) Could Be Quite Risky

Sep 30

Here's Why We're Watching Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation

Jun 03

What Kind Of Shareholders Hold The Majority In Freeline Therapeutics Holdings plc's (NASDAQ:FRLN) Shares?

Feb 18

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von FRLN in der Vergangenheit stabil geblieben ist.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von FRLN gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Freeline Therapeutics Holdings Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von FRLN im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (FRLN)	n/a
Untere 25 % des Marktes (US)	1.6%
Markt Top 25 % (US)	4.8%
Branchendurchschnitt (Biotechs)	2.8%
Analystenprognose in 3 Jahren (FRLN)	15.4%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von FRLN im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von FRLN im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von FRLN, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da FRLN keine Ausschüttungen gemeldet hat.

Freeline Therapeutics Holdings Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting

Freeline Therapeutics Files Form 15

Freeline Therapeutics Holdings plc(NasdaqCM:FRLN) dropped from NASDAQ Composite Index

Syncona Investment Management Limited completed the acquisition of the remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN).

Freeline Therapeutics Holdings' ADSs to be No Longer Listed on Nasdaq After Completion of Acquisition by Newly Established Portfolio Company of Syncona

Freeline Therapeutics Holdings' ADSs to be No Longer Listed on Nasdaq After Completion of Acquisition by Newly Established Portfolio Company of Syncona

Freeline Therapeutics Holdings plc Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate

Consensus revenue estimates decrease by 93%

Syncona Investment Management Limited has submitted a non-binding proposal to acquire remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN) for for $9.8 million.

Syncona Investment Management Limited has submitted a non-binding proposal to acquire remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN) for approximately $140 million.

Freeline Therapeutics Holdings plc Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 Galileo-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease

Price target increased by 12% to US$9.25

Consensus estimates of losses per share improve by 69%

Price target decreased by 24% to US$6.25

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)

New major risk - Share price stability

New major risk - Financial position

Freeline Therapeutics Holdings plc Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-Linked Parkinson's Disease

Consensus revenue estimates decrease by 19%, EPS upgraded

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2023

Freeline Therapeutics Holdings Regains Compliance with the Nasdaq Minimum Bid Price Requirement

Freeline Therapeutics Holdings plc Receives ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease

Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

Freeline Therapeutics Holdings plc Announces the Publication of Preclinical Proof-Of-Concept Data for Its Gene Therapy Candidate for Fabry Disease, FLT190

Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

Price target decreased to US$4.86

Freeline Initiates Dosing of Second Cohort in Marvel-1 Trial of Flt190 Gene Therapy Candidate for People with Fabry Disease

We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate

Price target decreased to US$6.71

Price target decreased to US$7.43

Freeline gains as NEJM publishes long-term data for hemophilia therapy

Freeline Therapeutics Holdings plc Announces Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

Freeline Therapeutics Holdings plc Announces Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress

Freeline Therapeutics Holdings plc Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B

Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2022

Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Invest In Growth?

Price target decreased to US$8.29

Freeline Therapeutics Holdings plc Appoints Paul Schneider as Chief Financial Officer

Price target decreased to US$9.33

Price target decreased to US$11.13

Freeline Therapeutics Holdings plc Appoints Henning R. Stennicke as Chief Scientific Officer

Will Freeline Therapeutics Holdings (NASDAQ:FRLN) Spend Its Cash Wisely?

Freeline Therapeutics Holdings plc Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1

Price target decreased to US$12.00

Freeline Therapeutics Holdings plc Presents Long-Term Follow-Up Data from Phase 1/2 B-AMAZE Trial in Hemophilia B at the 2021 ASH Annual Meeting and Announces Early Initiation of Phase 1/2 B-LIEVE Dose-Confirmation Trial

Companies Like Freeline Therapeutics Holdings (NASDAQ:FRLN) Could Be Quite Risky

High number of new directors

Chief Scientific Officer Romuald Corbau has left the company

CEO & Director Theresa Heggie has left the company

Price target decreased to US$18.25

Chief Development Officer Jan Thirkettle has left the company

Freeline Doses Second Patient of Phase 1/2 Marvel-1 Clinical Trial for Fabry Disease

Here's Why We're Watching Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation

Freeline Therapeutics Holdings plc Presents Data Highlighting Platform Technology At the American Society of Gene and Cell Therapy Annual Meeting 2021

CFO & Head of Corporate Development has left the company

Freeline Therapeutics Holdings plc Announces the Appointment of Colin A. Love to its Board of Directors

New 90-day low: US$15.06

What Kind Of Shareholders Hold The Majority In Freeline Therapeutics Holdings plc's (NASDAQ:FRLN) Shares?

Freeline Therapeutics Holdings plc Announces Management Changes

Freeline Therapeutics Holdings plc Presents Data on Its Gaucher Disease and Fabry Disease AAV-Based Gene Therapies at the 17 Annual WORLDSymposium™

Freeline Therapeutics Updates Clinical Development Plan for its FLT180a Hemophilia B Program

New 90-day high: US$18.30

Freeline Reports Updated Data From Phase 1/2 B-AMAZE Trial in Hemophilia B

New 90-day low: US$14.94

Freeline Therapeutics Holdings plc Appoints Mark Baldry as New Chief Commercial Officer

Freeline Therapeutics Holdings plc to Present New Data At the 12Th Annual Protein and Antibody Engineering Summit

Freeline Therapeutics Limited announced that it expects to receive funding from Syncona Partners LLP

Freeline Therapeutics Holdings plc Announces Executive Changes

Freeline Therapeutics Holdings plc Announces Supply Agreement with Thermo Fisher Scientific Inc. for Haemophilia B Program

Freeline Therapeutics Holdings plc Auditor Raises 'Going Concern' Doubt

Freeline Therapeutics Holdings plc has completed an IPO in the amount of $158.823522 million.

Stabilität und Wachstum des Zahlungsverkehrs